Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Plasma cell 1

Conditions

Multiple Myeloma 4Neoplasms 2Lymphoma 2Leukemia, Myeloid, Acute 2Leukemia 2Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms, Plasma Cell 1Lymphoma, Large B-Cell, Diffuse 1Hematologic Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 48fludarabine phosphate 36Methotrexate 26Cytarabine 24fludarabine 23Whole-Body Irradiation 23Rituximab 19Cyclosporine 19Antilymphocyte Serum 18Peripheral Blood Stem Cell Transplantation 17Filgrastim 17Busulfan 17Mycophenolic Acid 16Tacrolimus 15Azacitidine 15Alemtuzumab 15Radiotherapy 13Melphalan 13Imatinib Mesylate 13Etoposide 13Vincristine 11Methylprednisolone 11Cord Blood Stem Cell Transplantation 11Dexamethasone 10venetoclax 8Granulocyte Colony-Stimulating Factor 8Clofarabine 8thymoglobulin 7sargramostim 7nilotinib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Leukemia × isatuximab × Clear all
NCT03530683 2024-09-03

A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma

Pfizer

Phase 1 Terminated
189 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Multiple Myeloma, Neoplasms, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse, Neoplasms, Plasma Cell

NCT02999633 2022-03-21

ISLAY

Sanofi

Phase 2 Terminated
14 enrolled 7 charts
LymphoidOther hematologic neoplasm

Leukemia, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡